• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Addressing Unmet Needs with LP-284 for Relapsed/Refractory Lymphomas and Solid Tumors


In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to existing or emerging treatments for relapsed/refractory lymphomas and solid tumors.

The oncology landscape is crowded with novel therapies. How do you see LP-284 uniquely addressing unmet needs compared to existing or emerging treatments for relapsed/refractory lymphomas and solid tumors?

The thing about 284 is, you know, that is novel, it is mechanistically in a class, it's fairly well accepted and known, it's, you know, it's opposed to alkyl later. Now, it's a selective alkyl later, because it seems to really target cancer cells, or B cells and cancer cells. And not all cells, like most calculators, it also has, you know, several times more potency than most calculators. So, I think the fact that there's a known mechanism, it seems to prefer cancer cells, I think that makes it unique. And it's relatively more goal to scale and produce most of the other biologics out there. They're going after NHL today.

Can you speak on the anticipated timeline for a next stage and any key milestones to watch for as LP-284's development progresses?

The key things that we're going to be looking at this year is obviously in the phase one, to get to our maximum tolerated dose, that's going to be very important so that we can open up, you know, combination trials, we also expect to have some data toward the end of this year about LP 284 In other autoimmune conditions. So, we've actually started a campaign to look at LP 284 and LP284's mechanism in categories that we historically have not been in but are pretty significant. So that also excites us. And we'll have some data about that. And I think also we're beginning a lot of discussions with pharma partners that are historically have larger footprints in non Hodgkins lymphomas, because as I mentioned before, this drug shows remarkable synergy with some of the mainstays in non Hodgkins lymphomas like rituximab and cyclophosphamide, and some of those has great synergy potential.

So, when you think about patients that roll off of that or stop responding to that, effectively, we think that this drug can reenergize and actually be a great option for recurrent events for those patients, which today there aren't very many of them. That you know, as the data from the trial will tell us everything and will inform us where it's working best but will also guide us as to what sub indications are genetically defined populations and non Hodgkins lymphomas are even better responders. Right now, we go in with a thesis that mantle cell lymphoma and high grade B cell lymphoma, especially double hit and triple hit are going to be the ones that are most responsive based on all of our preclinical work and based on the in silico analysis that we've done. And if we can get a sense of that in the trial. And also, the trial, as you noted, probably is also open to a number of sarcomas.

So certainly, no sarcomas are genetically very, very, hugely heterogeneous. You know, some look more like solid tumors, some look with more like blood cancers, some look like a mishmash of things. And so, there are definitely some sarcomas that we're beginning to see some good data on in the early phase of this trial. And so, if we see some servos that are uniquely responsive, and as you know, some patients don't have a lot of options. And so that also could be something that opens up. We haven't applied for orphan indication in the sarcomas yet, but that's something that we'll probably do. And so, you'll one of the other events we'll see for 284 is expanding the number of orphan indications we have two already, and we think we'll probably gather a few others as we develop the drug.

Related Videos
Related Content